Serum transaminases in children with Wilson's disease.

Raffaele Iorio, Mariangela D'Ambrosi, Matilde Marcellini, Cristiana Barbera, Giuseppe Maggiore, Lucia Zancan, Raffaella Giacchino, Pietro Vajro, Maria Grazia Marazzi, Ruggiero Francavilla, Fabio Michielutti, Massimo Resti, Tullio Frediani, Maria Pastore, Giuseppina Mazzarella, Giuseppina Fusco, Francesco Cirillo, Angela Vegnente

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

OBJECTIVES: The response of serum transaminase levels to penicillamine and zinc treatment in Wilson's disease is poorly understood. The aim of this multicenter retrospective study was to evaluate transaminase levels after penicillamine and zinc treatment in children with Wilson's disease. PATIENTS AND METHODS: One hundred and nine patients with Wilson's disease (median age at diagnosis, 7.2 years; range, 1 to 18 years), treated for at least 12 months and observed in the last 20 years at 11 Paediatric Departments were studied. Clinical, laboratory and histologic features at diagnosis and initial treatment were recorded. Efficacy parameters were normalization of serum transaminase level and improved clinical and/or laboratory signs. One hundred and two patients had clinical or laboratory signs of liver disease. RESULTS: Fifty-six of 87 patients (64%) given penicillamine normalized serum alanine aminotransferase (ALT) levels within a median of 17 months (range, 2 to 96 months). Of the 29 patients with persistent hyper-ALT, 17 (59%) switched to zinc; only four of these normalized ALT on zinc within a median period of 38 months (range, 7 to 48 months). Eleven (50%) of the 22 patients given zinc alone normalized ALT within a median period of 6 months (range, 1 to 36 months). Of the 11 patients with persistent hyper-ALT, five switched to penicillamine. Three of the five normalized ALT within a median period of 6 months (range, 6 to 9 months). Overall, in penicillamine-treated and zinc-treated patients with persistent hypertransaminasemia, ALT decreased from a basal median of 236 IU/L (range, 54 to 640 IU/L) to a median of 78 (range, 46 to 960 IU/L) at the end of follow-up (P = 0.0245). Poor compliance was suspected in only 10% of cases. No predictive factor of persistent hypertransaminasemia was identified. Liver disease did not worsen in any patient during the study. CONCLUSIONS: Although the efficacy of penicillamine and zinc is well documented, it is notable that a subset of children with Wilson's disease-related liver disease (36%) had hypertransaminasemia despite appropriate treatment with penicillamine or zinc.

Original languageEnglish
Pages (from-to)331-336
Number of pages6
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume39
Issue number4
Publication statusPublished - Oct 2004

Fingerprint

hepatolenticular degeneration
penicillamine
Hepatolenticular Degeneration
transaminases
Penicillamine
Transaminases
Alanine Transaminase
alanine transaminase
Zinc
zinc
Serum
liver diseases
Liver Diseases
Therapeutics
retrospective studies
compliance
Multicenter Studies
Retrospective Studies
Pediatrics

ASJC Scopus subject areas

  • Gastroenterology
  • Histology
  • Medicine (miscellaneous)
  • Food Science
  • Pediatrics, Perinatology, and Child Health

Cite this

Iorio, R., D'Ambrosi, M., Marcellini, M., Barbera, C., Maggiore, G., Zancan, L., ... Vegnente, A. (2004). Serum transaminases in children with Wilson's disease. Journal of Pediatric Gastroenterology and Nutrition, 39(4), 331-336.

Serum transaminases in children with Wilson's disease. / Iorio, Raffaele; D'Ambrosi, Mariangela; Marcellini, Matilde; Barbera, Cristiana; Maggiore, Giuseppe; Zancan, Lucia; Giacchino, Raffaella; Vajro, Pietro; Marazzi, Maria Grazia; Francavilla, Ruggiero; Michielutti, Fabio; Resti, Massimo; Frediani, Tullio; Pastore, Maria; Mazzarella, Giuseppina; Fusco, Giuseppina; Cirillo, Francesco; Vegnente, Angela.

In: Journal of Pediatric Gastroenterology and Nutrition, Vol. 39, No. 4, 10.2004, p. 331-336.

Research output: Contribution to journalArticle

Iorio, R, D'Ambrosi, M, Marcellini, M, Barbera, C, Maggiore, G, Zancan, L, Giacchino, R, Vajro, P, Marazzi, MG, Francavilla, R, Michielutti, F, Resti, M, Frediani, T, Pastore, M, Mazzarella, G, Fusco, G, Cirillo, F & Vegnente, A 2004, 'Serum transaminases in children with Wilson's disease.', Journal of Pediatric Gastroenterology and Nutrition, vol. 39, no. 4, pp. 331-336.
Iorio R, D'Ambrosi M, Marcellini M, Barbera C, Maggiore G, Zancan L et al. Serum transaminases in children with Wilson's disease. Journal of Pediatric Gastroenterology and Nutrition. 2004 Oct;39(4):331-336.
Iorio, Raffaele ; D'Ambrosi, Mariangela ; Marcellini, Matilde ; Barbera, Cristiana ; Maggiore, Giuseppe ; Zancan, Lucia ; Giacchino, Raffaella ; Vajro, Pietro ; Marazzi, Maria Grazia ; Francavilla, Ruggiero ; Michielutti, Fabio ; Resti, Massimo ; Frediani, Tullio ; Pastore, Maria ; Mazzarella, Giuseppina ; Fusco, Giuseppina ; Cirillo, Francesco ; Vegnente, Angela. / Serum transaminases in children with Wilson's disease. In: Journal of Pediatric Gastroenterology and Nutrition. 2004 ; Vol. 39, No. 4. pp. 331-336.
@article{08b895ee2f97468db05d5497e7f4e968,
title = "Serum transaminases in children with Wilson's disease.",
abstract = "OBJECTIVES: The response of serum transaminase levels to penicillamine and zinc treatment in Wilson's disease is poorly understood. The aim of this multicenter retrospective study was to evaluate transaminase levels after penicillamine and zinc treatment in children with Wilson's disease. PATIENTS AND METHODS: One hundred and nine patients with Wilson's disease (median age at diagnosis, 7.2 years; range, 1 to 18 years), treated for at least 12 months and observed in the last 20 years at 11 Paediatric Departments were studied. Clinical, laboratory and histologic features at diagnosis and initial treatment were recorded. Efficacy parameters were normalization of serum transaminase level and improved clinical and/or laboratory signs. One hundred and two patients had clinical or laboratory signs of liver disease. RESULTS: Fifty-six of 87 patients (64{\%}) given penicillamine normalized serum alanine aminotransferase (ALT) levels within a median of 17 months (range, 2 to 96 months). Of the 29 patients with persistent hyper-ALT, 17 (59{\%}) switched to zinc; only four of these normalized ALT on zinc within a median period of 38 months (range, 7 to 48 months). Eleven (50{\%}) of the 22 patients given zinc alone normalized ALT within a median period of 6 months (range, 1 to 36 months). Of the 11 patients with persistent hyper-ALT, five switched to penicillamine. Three of the five normalized ALT within a median period of 6 months (range, 6 to 9 months). Overall, in penicillamine-treated and zinc-treated patients with persistent hypertransaminasemia, ALT decreased from a basal median of 236 IU/L (range, 54 to 640 IU/L) to a median of 78 (range, 46 to 960 IU/L) at the end of follow-up (P = 0.0245). Poor compliance was suspected in only 10{\%} of cases. No predictive factor of persistent hypertransaminasemia was identified. Liver disease did not worsen in any patient during the study. CONCLUSIONS: Although the efficacy of penicillamine and zinc is well documented, it is notable that a subset of children with Wilson's disease-related liver disease (36{\%}) had hypertransaminasemia despite appropriate treatment with penicillamine or zinc.",
author = "Raffaele Iorio and Mariangela D'Ambrosi and Matilde Marcellini and Cristiana Barbera and Giuseppe Maggiore and Lucia Zancan and Raffaella Giacchino and Pietro Vajro and Marazzi, {Maria Grazia} and Ruggiero Francavilla and Fabio Michielutti and Massimo Resti and Tullio Frediani and Maria Pastore and Giuseppina Mazzarella and Giuseppina Fusco and Francesco Cirillo and Angela Vegnente",
year = "2004",
month = "10",
language = "English",
volume = "39",
pages = "331--336",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Serum transaminases in children with Wilson's disease.

AU - Iorio, Raffaele

AU - D'Ambrosi, Mariangela

AU - Marcellini, Matilde

AU - Barbera, Cristiana

AU - Maggiore, Giuseppe

AU - Zancan, Lucia

AU - Giacchino, Raffaella

AU - Vajro, Pietro

AU - Marazzi, Maria Grazia

AU - Francavilla, Ruggiero

AU - Michielutti, Fabio

AU - Resti, Massimo

AU - Frediani, Tullio

AU - Pastore, Maria

AU - Mazzarella, Giuseppina

AU - Fusco, Giuseppina

AU - Cirillo, Francesco

AU - Vegnente, Angela

PY - 2004/10

Y1 - 2004/10

N2 - OBJECTIVES: The response of serum transaminase levels to penicillamine and zinc treatment in Wilson's disease is poorly understood. The aim of this multicenter retrospective study was to evaluate transaminase levels after penicillamine and zinc treatment in children with Wilson's disease. PATIENTS AND METHODS: One hundred and nine patients with Wilson's disease (median age at diagnosis, 7.2 years; range, 1 to 18 years), treated for at least 12 months and observed in the last 20 years at 11 Paediatric Departments were studied. Clinical, laboratory and histologic features at diagnosis and initial treatment were recorded. Efficacy parameters were normalization of serum transaminase level and improved clinical and/or laboratory signs. One hundred and two patients had clinical or laboratory signs of liver disease. RESULTS: Fifty-six of 87 patients (64%) given penicillamine normalized serum alanine aminotransferase (ALT) levels within a median of 17 months (range, 2 to 96 months). Of the 29 patients with persistent hyper-ALT, 17 (59%) switched to zinc; only four of these normalized ALT on zinc within a median period of 38 months (range, 7 to 48 months). Eleven (50%) of the 22 patients given zinc alone normalized ALT within a median period of 6 months (range, 1 to 36 months). Of the 11 patients with persistent hyper-ALT, five switched to penicillamine. Three of the five normalized ALT within a median period of 6 months (range, 6 to 9 months). Overall, in penicillamine-treated and zinc-treated patients with persistent hypertransaminasemia, ALT decreased from a basal median of 236 IU/L (range, 54 to 640 IU/L) to a median of 78 (range, 46 to 960 IU/L) at the end of follow-up (P = 0.0245). Poor compliance was suspected in only 10% of cases. No predictive factor of persistent hypertransaminasemia was identified. Liver disease did not worsen in any patient during the study. CONCLUSIONS: Although the efficacy of penicillamine and zinc is well documented, it is notable that a subset of children with Wilson's disease-related liver disease (36%) had hypertransaminasemia despite appropriate treatment with penicillamine or zinc.

AB - OBJECTIVES: The response of serum transaminase levels to penicillamine and zinc treatment in Wilson's disease is poorly understood. The aim of this multicenter retrospective study was to evaluate transaminase levels after penicillamine and zinc treatment in children with Wilson's disease. PATIENTS AND METHODS: One hundred and nine patients with Wilson's disease (median age at diagnosis, 7.2 years; range, 1 to 18 years), treated for at least 12 months and observed in the last 20 years at 11 Paediatric Departments were studied. Clinical, laboratory and histologic features at diagnosis and initial treatment were recorded. Efficacy parameters were normalization of serum transaminase level and improved clinical and/or laboratory signs. One hundred and two patients had clinical or laboratory signs of liver disease. RESULTS: Fifty-six of 87 patients (64%) given penicillamine normalized serum alanine aminotransferase (ALT) levels within a median of 17 months (range, 2 to 96 months). Of the 29 patients with persistent hyper-ALT, 17 (59%) switched to zinc; only four of these normalized ALT on zinc within a median period of 38 months (range, 7 to 48 months). Eleven (50%) of the 22 patients given zinc alone normalized ALT within a median period of 6 months (range, 1 to 36 months). Of the 11 patients with persistent hyper-ALT, five switched to penicillamine. Three of the five normalized ALT within a median period of 6 months (range, 6 to 9 months). Overall, in penicillamine-treated and zinc-treated patients with persistent hypertransaminasemia, ALT decreased from a basal median of 236 IU/L (range, 54 to 640 IU/L) to a median of 78 (range, 46 to 960 IU/L) at the end of follow-up (P = 0.0245). Poor compliance was suspected in only 10% of cases. No predictive factor of persistent hypertransaminasemia was identified. Liver disease did not worsen in any patient during the study. CONCLUSIONS: Although the efficacy of penicillamine and zinc is well documented, it is notable that a subset of children with Wilson's disease-related liver disease (36%) had hypertransaminasemia despite appropriate treatment with penicillamine or zinc.

UR - http://www.scopus.com/inward/record.url?scp=30744436753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30744436753&partnerID=8YFLogxK

M3 - Article

C2 - 15448420

AN - SCOPUS:30744436753

VL - 39

SP - 331

EP - 336

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 4

ER -